Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure.
Jevnikar A, Arlen D, Barrett B, Boucher A, Cardella C, Cockfield SM, Rush D, Paraskevas S, Shapiro J, Shoker A, Yilmaz S, Zaltzman JS, Kiberd B. Transplantation. 2008 Oct 15;86(7):953-60
Related Articles:
- Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study.
- Comparison of Sirolimus Plus Tacrolimus Versus Sirolimus Plus Cyclosporine in High-Risk Renal Allograft Recipients: Results From an Open-Label, Randomized Trial.
- A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
Recent Comments